Telomir Pharmaceuticals (TELO) Expected to Announce Quarterly Earnings on Tuesday

Telomir Pharmaceuticals (NASDAQ:TELO) is anticipated to announce its results before the market opens on Tuesday, February 3rd. Analysts expect the company to announce earnings of ($0.07) per share for the quarter.

Telomir Pharmaceuticals (NASDAQ:TELO) last released its quarterly earnings results on Monday, November 10th. The company reported ($0.03) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.07) by $0.04. On average, analysts expect Telomir Pharmaceuticals to post $0 EPS for the current fiscal year and $0 EPS for the next fiscal year.

Telomir Pharmaceuticals Trading Down 1.5%

Shares of NASDAQ:TELO opened at $1.32 on Tuesday. The business has a 50-day moving average price of $1.37 and a 200 day moving average price of $1.47. The company has a market capitalization of $45.38 million, a price-to-earnings ratio of -3.57 and a beta of -0.49. Telomir Pharmaceuticals has a 12-month low of $1.12 and a 12-month high of $5.40.

Analyst Upgrades and Downgrades

A number of equities research analysts have weighed in on TELO shares. Rodman & Renshaw started coverage on shares of Telomir Pharmaceuticals in a research report on Tuesday, January 13th. They set a “buy” rating for the company. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Telomir Pharmaceuticals in a research report on Thursday. One investment analyst has rated the stock with a Buy rating and one has given a Sell rating to the company. According to data from MarketBeat.com, Telomir Pharmaceuticals has a consensus rating of “Hold” and a consensus target price of $15.00.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently made changes to their positions in the business. Qube Research & Technologies Ltd acquired a new position in shares of Telomir Pharmaceuticals in the second quarter valued at approximately $33,000. Bank of America Corp DE lifted its holdings in Telomir Pharmaceuticals by 283.9% during the 4th quarter. Bank of America Corp DE now owns 14,713 shares of the company’s stock worth $61,000 after buying an additional 10,880 shares in the last quarter. Jane Street Group LLC purchased a new position in Telomir Pharmaceuticals in the 2nd quarter valued at approximately $62,000. Marshall Wace LLP acquired a new position in shares of Telomir Pharmaceuticals in the second quarter worth $95,000. Finally, Raymond James Financial Inc. grew its stake in shares of Telomir Pharmaceuticals by 4,101.9% in the third quarter. Raymond James Financial Inc. now owns 75,340 shares of the company’s stock worth $105,000 after acquiring an additional 73,547 shares in the last quarter.

Telomir Pharmaceuticals Company Profile

Telomir Pharmaceuticals, Inc (NASDAQ: TELO) is a clinical-stage biopharmaceutical company focused on the discovery and development of novel small-molecule therapies for cardiometabolic and fibrotic diseases. Leveraging a proprietary target discovery platform, the company aims to identify and modulate key biological pathways implicated in tissue fibrosis, inflammation and metabolic dysregulation. Its research strategy centers on oral agents intended to address high-unmet-need conditions such as nonalcoholic steatohepatitis (NASH) and systemic fibrotic disorders, where existing treatment options are limited.

The company’s lead development candidate is an oral inhibitor currently in early-phase clinical trials that targets growth factors involved in fibrotic tissue remodeling.